Search

Your search keyword '"Gensuke Takayama"' showing total 2 results
Start Over Author "Gensuke Takayama" Publisher elsevier
2 results on '"Gensuke Takayama"'

1. Improvement of Pulmonary Function by Oral Treatment with a VLA-4 Antagonist in a Mouse Asthmatic Model

Author

Gensuke Takayama, Keiko Matsumoto, Tomoe Taira, Misato Aonuma, Mika Yokoyama, Yutaka Iigo, and Tohru Takashi

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

We investigated in vivo efficacies of the newly synthesized VLA-4 antagonist Compound A {trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid} on Ascaris antigen–induced airway inflammation and hyperresponsiveness in a murine asthmatic model. Oral administration of Compound A significantly inhibited eosinophil infiltration into BALF and airway hyperresponsiveness 48 h after the antigen challenge. Histologic analysis of the lung sections confirmed the BALF result and revealed suppression of edema and mucus hyperplasia at 8 and 48 h after the challenge, respectively. These findings clearly show that orally active Compound A has therapeutic potential for treatment of asthma. Keywords:: VLA-4, eosinophil, airway hyperresponsiveness

Published
2013
Full Text
View/download PDF

2. Improvement of Pulmonary Function by Oral Treatment with a VLA-4 Antagonist in a Mouse Asthmatic Model

Author

Keiko Matsumoto, Misato Aonuma, Tomoe Taira, Gensuke Takayama, Yutaka Iigo, Tohru Takashi, and Mika Yokoyama

Subjects
Pyrrolidines, Time Factors, Cyclohexanecarboxylic Acids, Respiratory System, Administration, Oral, Pharmacology, Integrin alpha4beta1, Mice, In vivo, Oral administration, Edema, medicine, Animals, Lung, Inflammation, business.industry, Anti-Inflammatory Agents, Non-Steroidal, lcsh:RM1-950, Antagonist, Eosinophil, Hyperplasia, respiratory system, medicine.disease, Mucus, Acetylcholine, Asthma, respiratory tract diseases, Eosinophils, Disease Models, Animal, medicine.anatomical_structure, lcsh:Therapeutics. Pharmacology, Immunology, Molecular Medicine, Female, medicine.symptom, business, Bronchoalveolar Lavage Fluid
Abstract

We investigated in vivo efficacies of the newly synthesized VLA-4 antagonist Compound A {trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid} on Ascaris antigen–induced airway inflammation and hyperresponsiveness in a murine asthmatic model. Oral administration of Compound A significantly inhibited eosinophil infiltration into BALF and airway hyperresponsiveness 48 h after the antigen challenge. Histologic analysis of the lung sections confirmed the BALF result and revealed suppression of edema and mucus hyperplasia at 8 and 48 h after the challenge, respectively. These findings clearly show that orally active Compound A has therapeutic potential for treatment of asthma. Keywords:: VLA-4, eosinophil, airway hyperresponsiveness

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results